Participated · Series A · Aug 2026

Leal Therapeutics focuses on developing neuro-metabolic treatments for high-need central nervous system disorders and was launched in 2021. Its lead program, LTX-001, is a brain-penetrant oral GLS1 inhibitor that completed single and multiple ascending dose Phase 1 trials and has initiated a Phase 1b/2a trial in adults with schizophrenia with initial data expected by year-end. A second program, LTX-002, is an intrathecally delivered antisense oligonucleotide targeting SPTLC1 and is being evaluated in the NeurALS Phase 1/2 trial in adults with ALS. The company also is developing a next-generation CNS delivery platform using antibody-like shuttle technology to enable transport of peripherally administered therapeutics to the brain. Leal states it has capabilities to develop and produce both small molecule and nucleic acid CNS therapeutics. The recent Series A second close of $30 million, which added Eli Lilly to its investor syndicate, is intended to support clinical milestones for LTX-001 and additional dosing cohorts for LTX-002.

Led · Series B · May 2026

CREATE Medicines develops in vivo immune programming therapies by delivering proprietary mRNA-LNP constructs that directly engineer T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. Its lead autoimmune program, CRT-402, is a next-generation CD19 targeted in vivo CAR-T candidate with demonstrated deep and durable B cell depletion in non-human primates and designed for repeat dosing; the company is also advancing a dual CAR CD19 x BCMA program to broaden reach across refractory autoimmune indications. In oncology, CREATE is advancing multiple programs, including MT-303, which has shown compelling early clinical responses in frontline hepatocellular carcinoma. The company reports dosing more than 50 patients across its in vivo CAR clinical programs, which it cites as the largest clinical dataset in the field. CREATE highlights integration of clinically validated CAR architectures, optimized RNA design, targeted delivery technologies, and ownership of manufacturing infrastructure as core competitive advantages. Recent leadership additions include Ron Philip as Executive Chairman and new board members from ARCH Venture Partners and Newpath Partners.

Led · Equity · Dec 2024

nChroma Bio was formed by the merger of Chroma Medicine and Nvelop Therapeutics to combine potent epigenetic editing cargos with programmable non-viral in vivo delivery. Its lead program, CRMA-1001, is a liver-targeted epigenetic editor being developed as a potential functional cure for chronic hepatitis B and hepatitis D. In preclinical models CRMA-1001 achieved deep and durable reductions of key hepatitis B and D viral biomarkers. The company emphasizes that its epigenetic editors modulate gene expression without cutting or nicking DNA, avoiding activation of DNA repair pathways and potential genomic rearrangement. nChroma plans to submit a clinical trial application for CRMA-1001 in 2025 and to build a pipeline of hepatic and extrahepatic targeted therapies using its programmable delivery vehicles. The merger, leadership appointments, and an oversubscribed $75 million financing provide multiple years of runway to advance the platform and lead candidate.

Participated · Series B · Nov 2024

Metsera is a clinical-stage biopharmaceutical company developing next-generation peptide medicines for obesity and metabolic diseases, built on its HALO™ lipidation and MOMENTUM™ oral delivery platforms. The company has three medicines in the clinic, including MET-097i, MET-233i and MET-002, and is advancing additional NuSH analog peptides and unimolecular combinations. MET-097i, a fully-biased, ultra-long acting injectable GLP-1 RA, showed 7.5% body-weight reduction at day 36 and a 380-hour half-life in Phase 1/2 testing and is now in a randomized 16-week Phase 2 trial. MET-233i (an ultra-long acting amylin analog) and MET-002 (an oral GLP-1 RA peptide) have initiated clinical studies. Metsera says its HALO™ platform enables near-albumin half-lives and monthly, titration-free dosing, while MOMENTUM™ aims to deliver injectable-like oral peptide efficacy at lower doses. The company has built a large proprietary peptide library and is pursuing combinations, co-formulations, and scaled manufacturing to support late-stage development. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies designed to address obesity and metabolic diseases. Its pipeline is sourced from a proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. Development programs include a Phase 1 fully-biased GLP-1 receptor agonist, a dual amylin/calcitonin receptor agonist (DACRA) combined with the GLP-1 agonist, a unimolecular GGG (GLP-1, GIP, Glucagon), and an oral peptide delivery platform with two IND-ready candidates. The company says its portfolio is engineered for class-leading duration of effect and aims to address future needs such as weight maintenance, muscle preservation, less-frequent dosing, improved efficacy and tolerability, and better patient access. Founded in 2022 by Population Health Partners and ARCH Venture Partners and led by CEO Clive Meanwell, Metsera is positioning to rapidly advance its clinical-stage pipeline. Metsera has raised $290 million in financing to support development from its New York City base.

Led · Series C · Jul 2024

Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders using a brain-targeting chemistry platform. Its lead program, ABX-002, is an oral, selective thyroid hormone beta receptor (TRβ) agonist that showed CNS target engagement and favorable tolerability in Phase 1. The company plans to initiate two Phase 2 trials of ABX-002 in the second half of 2024 as adjunctive treatment for major depressive disorder and bipolar depression. Autobahn will also advance ABX-101, a highly CNS-penetrant oral S1P receptor modulator, into Phase 1 clinical testing to target neuroimmunologic and neuroinflammatory disorders. Preclinical data for ABX-101 demonstrated exceptional CNS exposure and robust centrally mediated effects in animal models. The company is based in San Diego and intends to use recent financing to rapidly progress these programs through clinical development. Autobahn Therapeutics leverages a proprietary brain‑targeting chemistry platform to develop precision CNS therapeutics. Its lead program, ABX‑002, is a potent, selective thyroid receptor‑beta (TRβ) agonist designed to augment antidepressant effects and enhance serotonin activity in treatment‑resistant depression (TRD) patients. The company plans to initiate a Phase 1 single‑ and multiple‑ascending dose trial of ABX‑002 in healthy volunteers in the second half of 2022. Autobahn has assembled a TRD‑focused scientific advisory board with leaders from neurology, psychiatry and drug development to guide its program. Beyond TRD, Autobahn will evaluate ABX‑002 for additional indications including remyelination and multiple sclerosis and will use its chemistry platform to identify further programs. The company is based in San Diego. Autobahn Therapeutics is focused on developing next-generation regenerative medicines for CNS disorders by leveraging a brain-targeting chemistry platform and validated thyroid hormone biology. Its lead program, ABX-002, is a thyroid hormone receptor beta agonist being developed for multiple sclerosis and adrenomyeloneuropathy. The company develops small-molecule thyromimetics designed to stimulate remyelination and selectively maximize exposure in the brain. Autobahn intends to use biomarker-driven development to establish on-target activity and early proof-of-mechanism. Leadership includes experienced executives and scientific founders such as Kevin Finney (CEO) and Thomas Scanlan (co-founder and senior advisor). The company is advancing a broader portfolio of CNS programs built on the same platform and has just completed a significant Series B financing to fund near-term development.